Education
About Us
Working with TipRanks
Follow Us
Lantern Pharma, Inc. (LTRN)
:LTRN
LTRN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.79 - $8.27
Previous CloseN/A
Volume32.66K
Average Volume (3M)33.39K
Market Cap
$35.05M
Enterprise Value$10.63M
Total Cash (Recent Filing)$37.20M
Total Debt (Recent Filing)$52.89K
Price to Earnings (P/E)―
Beta2.41
Next Earnings
May 06, 2025EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.93
Shares Outstanding10,784,725
10 Day Avg. Volume31,428
30 Day Avg. Volume33,388
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.30
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.50
Forecast
1Y Price Target
$25.00Price Target Upside736.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Lantern Pharma News
PremiumCompany Announcements
Lantern Pharma’s Earnings Call: AI Advances Amid Financial Challenges
PremiumCompany Announcements
Lantern Pharma Advances AI-Driven Oncology Pipeline
PremiumCompany Announcements
Lantern Pharma Reports Q4 2024 Financial Results and AI Progress
PremiumCompany Announcements
Lantern Pharma Extends CSO’s Employment Agreement---
Ownership Overview
22.88% Insiders
4.33% Mutual Funds
15.08% Other Institutional Investors
53.94% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
LTRN FAQ
What was Lantern Pharma, Inc.’s price range in the past 12 months?
Lantern Pharma, Inc. lowest stock price was $2.79 and its highest was $8.27 in the past 12 months.
What is Lantern Pharma, Inc.’s market cap?
Lantern Pharma, Inc.’s market cap is $35.05M.
When is Lantern Pharma, Inc.’s upcoming earnings report date?
Lantern Pharma, Inc.’s upcoming earnings report date is May 06, 2025 which is in 30 days.
How were Lantern Pharma, Inc.’s earnings last quarter?
Lantern Pharma, Inc. released its earnings results on Mar 27, 2025. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.51 by -$0.03.
Is Lantern Pharma, Inc. overvalued?
According to Wall Street analysts Lantern Pharma, Inc.’s price is currently Undervalued.
Does Lantern Pharma, Inc. pay dividends?
Lantern Pharma, Inc. does not currently pay dividends.
What is Lantern Pharma, Inc.’s EPS estimate?
Lantern Pharma, Inc.’s EPS estimate is -0.49.
How many shares outstanding does Lantern Pharma, Inc. have?
Lantern Pharma, Inc. has 10,784,725 shares outstanding.
What happened to Lantern Pharma, Inc.’s price movement after its last earnings report?
Lantern Pharma, Inc. reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.51. Following the earnings report the stock price went down -4.57%.
Which hedge fund is a major shareholder of Lantern Pharma, Inc.?
Currently, no hedge funds are holding shares in LTRN
---
Lantern Pharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.00 (736.12% Upside)
$25.00 (736.12% Upside)
Hedge Fund Trend
Decreased
By 10.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.8%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.58%
12-Months-Change
Fundamentals
Return on Equity
-66.93%
Trailing 12-Months
Asset Growth
-41.41%
Trailing 12-Months
Company Description
Lantern Pharma, Inc.
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
---
LTRN Company Deck
---
LTRN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Lantern Pharma has made notable advancements in AI-driven oncology drug development, achieving significant clinical trial milestones and regulatory designations. However, financial challenges persist with increased operational losses and future funding needs.Read More>---
LTRN Stock 12 Month Forecast
Average Price Target
$25.00
▲(736.12% Upside)
Technical Analysis
Best Analysts Covering LTRN
1 Year
Unknown AnalystLake Street
Not Ranked
1 Year Success Rate
0/0 ratings generated profit
1 Year Average Return
0.00%
initiated a buy rating 5 days ago
Copying Unknown Analyst's trades and holding each position for 1 Year would result in - of your transactions generating a profit, with an average return of 0.00% per trade.
---